Dendreon has named Dennis M. Fenton to the board of directors, effective November 8, 2011.

Fenton has 30 years of pharmaceutical and biotechnology experience, including over two decades at Amgen. Prior to joining Amgen, Fenton served as senior research scientist at Pfizer.

“Dennis is one of the true pioneers of biotechnology, playing a key role in the development and manufacturing of truly innovative therapies, which is relevant to the work we’re doing at Dendreon, particularly as we leverage our fixed commercial infrastructure to efficiently meet a large unmet medical need for patients through the commercialization of PROVENGE,” said Mitchell H. Gold, MD, president and chief executive officer.